Breast Cancer Histopathology Employs Infrared Spectroscopic Imaging
By LabMedica International staff writers Posted on 19 Apr 2021 |

Image: Spatial and quantitative comparison of high-definition (HD) and standard definition (SD) classification performance using the 6-class model (Photo courtesy of University of Illinois at Urbana−Champaign)
Digital analysis of cancer specimens using spectroscopic imaging coupled to machine learning is an emerging area that links spatially localized spectral signatures to tissue structure and disease. Breast histopathology, as an example of the broad relevance of these techniques, is critically important for clinical diagnoses.
Current histologic characterization is morphology-based; thin tissue sections are stained, and cells are visually recognized by a pathologist using an optical microscope. However, the basis of the disease is well known to be molecular. Molecular analysis for pathology is complicated by the spatial diversity of cells and acellular materials, necessitating an analytical technique that involves imaging.
Bioengineers at the University of Illinois at Urbana−Champaign (Urbana, IL, USA) and their colleagues examined the role of spatial-spectral tradeoffs in infrared spectroscopic imaging configurations for probing tumors and the associated microenvironment profiles at different levels of model complexity. The imaged breast tissue using standard and high-definition Fourier Transform Infrared (FT-IR) imaging and systematically examine the localization, spectral origins, and utility of data for classification.
The team obtained formalin-fixed, paraffin-embedded serial breast tissue microarrays (TMA) sections. The array consisted of a total of 101 cores of 1 mm diameter from 47 patients. Two sections were stained with hematoxylin and eosin (H&E) and other immunohistochemical markers and imaged with a light microscope. High-definition (HD) FT-IR imaging was conducted using the Agilent Stingray imaging system (Santa Clara, CA, USA) which is comprised of a 680-IR spectrometer coupled to a 620-IR imaging microscope with 0.62 numerical aperture, 25×objective.
The scientists provided a systematic comparison in the use of HD and SD FT-IR imaging data for breast pathology in their study. While the increased spatial localization of spectral signals in HD imaging may have been expected to provide a confounding influence, the study demonstrated that accuracy can be high, and there is significant potential in this sampling mode offering higher sensitivity. The team stated that IR imaging can not only provide the recognition capability of molecular data but can also balance that with an increased quality of morphologic data.
Rohit Bhargava, PhD, bioengineering professor and senior author of the study, said, “As technology expands and provides more capabilities with new features, it becomes more difficult to choose the optimal technology from the many options available. This study provides a nice comparison and guidelines to design a more useful and practical technology.” The study was originally published on February 27, 2021 in the journal Clinical Spectroscopy.
Related Links:
University of Illinois at Urbana−Champaign
Current histologic characterization is morphology-based; thin tissue sections are stained, and cells are visually recognized by a pathologist using an optical microscope. However, the basis of the disease is well known to be molecular. Molecular analysis for pathology is complicated by the spatial diversity of cells and acellular materials, necessitating an analytical technique that involves imaging.
Bioengineers at the University of Illinois at Urbana−Champaign (Urbana, IL, USA) and their colleagues examined the role of spatial-spectral tradeoffs in infrared spectroscopic imaging configurations for probing tumors and the associated microenvironment profiles at different levels of model complexity. The imaged breast tissue using standard and high-definition Fourier Transform Infrared (FT-IR) imaging and systematically examine the localization, spectral origins, and utility of data for classification.
The team obtained formalin-fixed, paraffin-embedded serial breast tissue microarrays (TMA) sections. The array consisted of a total of 101 cores of 1 mm diameter from 47 patients. Two sections were stained with hematoxylin and eosin (H&E) and other immunohistochemical markers and imaged with a light microscope. High-definition (HD) FT-IR imaging was conducted using the Agilent Stingray imaging system (Santa Clara, CA, USA) which is comprised of a 680-IR spectrometer coupled to a 620-IR imaging microscope with 0.62 numerical aperture, 25×objective.
The scientists provided a systematic comparison in the use of HD and SD FT-IR imaging data for breast pathology in their study. While the increased spatial localization of spectral signals in HD imaging may have been expected to provide a confounding influence, the study demonstrated that accuracy can be high, and there is significant potential in this sampling mode offering higher sensitivity. The team stated that IR imaging can not only provide the recognition capability of molecular data but can also balance that with an increased quality of morphologic data.
Rohit Bhargava, PhD, bioengineering professor and senior author of the study, said, “As technology expands and provides more capabilities with new features, it becomes more difficult to choose the optimal technology from the many options available. This study provides a nice comparison and guidelines to design a more useful and practical technology.” The study was originally published on February 27, 2021 in the journal Clinical Spectroscopy.
Related Links:
University of Illinois at Urbana−Champaign
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more